2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.

about

2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.

Item

http://www.wikidata.org/entity/Q53821957

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

2016 Children's Tumor Foundati ...... s type 2, and schwannomatosis.

@en

2016 Children's Tumor Foundati ...... s type 2, and schwannomatosis.

@nl

type

Item

label

2016 Children's Tumor Foundati ...... s type 2, and schwannomatosis.

@en

2016 Children's Tumor Foundati ...... s type 2, and schwannomatosis.

@nl

prefLabel

2016 Children's Tumor Foundati ...... s type 2, and schwannomatosis.

@en

2016 Children's Tumor Foundati ...... s type 2, and schwannomatosis.

@nl

P1476

2016 Children's Tumor Foundati ...... is type 2, and schwannomatosis

@en

P2093

AeRang Kim

http://www.w3.org/2001/XMLSchema#string

Allan J Belzberg

http://www.w3.org/2001/XMLSchema#string

Brian Weiss

http://www.w3.org/2001/XMLSchema#string

Brigitte C Widemann

http://www.w3.org/2001/XMLSchema#string

Conxi Lázaro

http://www.w3.org/2001/XMLSchema#string

David Viskochil

http://www.w3.org/2001/XMLSchema#string

Elisabeth Schorry

http://www.w3.org/2001/XMLSchema#string

Florent Elefteriou

http://www.w3.org/2001/XMLSchema#string

Gordon J Harris

http://www.w3.org/2001/XMLSchema#string

Helen Morrison

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas.

A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.

Recommendations for imaging tumor response in neurofibromatosis clinical trials.

Optimizing biologically targeted clinical trials for neurofibromatosis.

Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.

MEG detection of delayed auditory evoked responses in autism spectrum disorders: towards an imaging biomarker for autism

Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1.

Peripheral muscle weakness in RASopathies.

Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.

Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation

P304

1258-1269

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/AJMG.A.38675

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

176

http://www.w3.org/2001/XMLSchema#string

P50

Matthias A. Karajannis

Annette Bakker

Lu Q Le

Michael J Fisher

P577

2018-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29681099

http://www.w3.org/2001/XMLSchema#string

P932

5918269

http://www.w3.org/2001/XMLSchema#string